Other

Pfizer beats 3Q expectations, raises 2015 earnings forecast

Pfizer Inc., finally turning the corner after years of generic competition that slashed revenue from the drugmaker's former blockbusters, easily beat Wall Street expectations for the third quarter and raised its 2015 earnings ...

Other

Actavis plans name change to Allergan

Drugmaker Actavis is planning to change its name as it draws closer to finishing another big deal, the $66 billion purchase of Botox maker Allergan that it announced last fall.

Diseases, Conditions, Syndromes

New study reveals crippling financial burden of leprosy

Households affected by leprosy face being pushed further into poverty as a result of loss of earnings and treatment costs, according to the first ever study of the economic burden of a common complication of the disease.

Other

Mallinckrodt buying Cadence Pharma for $1.21B

Health care products company Mallinckrodt is buying Cadence Pharmaceuticals Inc. for about $1.21 billion to help enhance its specialty pharmaceuticals segment.

page 3 from 5